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Abstract The objective of the study is to investigate potential
citrullinated autoantigens as targets of anti-citrullinated pro-
tein antibodies (ACPAs) response in synovial fluids (SFs) of
patients with rheumatoid arthritis (RA). SFs from six RA pa-
tients and six osteoarthritis (OA) patients as controls were
collected. The citrullinated proteins in SFs were extracted by
immunoprecipitation with rabbit anti-citrulline antibodies.
Matrix-assisted laser desorption/ionization time of flight mass
spectrometry/time of flight mass spectrometry (MALDI-TOF/
TOF) mass spectrometry was subsequently performed to dis-
cover a characteristic neutral loss to finally determine
citrullinated autoantigens. A total of 182 citrullinated peptides
and 200 citrullinated sites were identified in RA SFs, while 3
citrullinated peptides and 4 citrullinated sites were identified
in OA SFs. The 182 citrullinated peptides from RA SFs and
the 3 citrullinated peptides fromOASFswere derived from 83
and 3 autoantigens, respectively. Eighty-three autoantigens
except protein-arginine deiminase type-2 (PADI2) and
protein-arginine deiminase type-2 (PADI4) were over-
citrullinated compared with controls, and the citrullinated sites
of PADI2 and PADI4 were different in two groups.
Interestingly, citrullinated histone H3.3 (H3F3A) was found
in OA controls, but not in RA groups. The differential
citrullinated proteins identified in RA SFs suggested potential
autoantigens were targeted for ACPAs response and might
contribute to the induction and perpetuation of complement
activation and joint inflammation in RA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by the formation of inflammatory, invasive tissue, and
rheumatoid pannus in synovial membranes, subsequently
resulting in joint destruction and systemic complications.
The related autoimmunity is often associated with certain ma-
jor histocompatibility complex (MHC) types and the presence
of anti-citrullinated protein antibodies (ACPAs) [1]. ACPAs
are important biomarkers of RA and can be detected even
before the clinical onset of the disease; consequently, they
are recognized as a predictive and diagnostic marker.
Furthermore, ACPAs in the inflammatory synovium bind to
citrullinated autoantigens to form immune complexes (ICs),
which lead to the development of inflammation [2–7]. Thus, a
simple and effective method is needed to detect citrullinated
proteins in the joint fluid from RA patients.
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Citrullination is a post-translational modification (PTM)
involving the conversion of an arginine residue to a non-
coded citrulline residue, catalyzed by peptidylarginine
deiminases (PADIs). This PTM leads to the loss of a positive
charge and a reduction in hydrogen-bonding ability [8]. The
traditional method to detect citrullinated proteins in biological
fluids is two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE) followed by immunoblotting and Fourier trans-
form ion cyclotron resonance (ICR) mass spectrometry (MS)
analysis, which is labor-intensive and time-consuming [9–12].
Moreover, the mass shift of citrullination is very small
(+1 Da), which can result in false positives [4,13]. Hao et al.
[14] found that one specific signature of citrullination is that
the neutral loss of 43 Da from the peptidyl-citrulline can be
observed after collision-induced dissociation (CID) during tri-
ple quadruple/linear ion trap (Q-Trap) mass spectrometry,
which indicates the elimination of isocyanic acid from the
citrulline ureido group as shown in (Fig. 1). However, this
technology has not been applied to human fluid because the
complexity of the protein mixture made detection of low-
abundance proteins very difficult. In addition, the low mass
resolution of Q-trap MS prevented the reliable peptide and
PTM characterization as in the high mass resolution of time-
of-flight (TOF) MS. Thus, we first applied liquid
chromatography-matrix-assisted laser desorption/ionization
(LC-MALDI)-TOF/TOF to detect citrullinated proteins in hu-
man RA synovial fluid (SF).
In this study, citrullinated proteins were extracted by im-
munoprecipitation using agarose-conjugated rabbit anti-
citrulline antibodies, followed by LC-MALDI-TOF/TOF
MS analysis. The peptide sequences and citrullinated sites in
RA SFs or osteoarthritis (OA) SFs were identified. The high-
energy CID mode of MALDI-TOF/TOF (20 keV collision
energy) was adopted to improve fragmentation efficiency for
reliable peptide and PTM characterization, thereby enabling
the identification of potential autoantigens for ACPAs.
Methods
Human sample collection
Samples of SFs were consecutively obtained from knee joints
of patients with RA or patients with OA, as a control, during
knee therapeutic arthrocentesis at the Department Osteology,
Jinling Hospital, School of Medicine, Nanjing University
from January 2011 to January 2012. In order to improve the
possibility of the existence of citrullinated antigens, patients of
RA fulfilling the criteria (serum ACPA >200 U/ml and syno-
vial fluids ACPA >200 U/ml) were selected and SFs of pa-
tients whowere diagnosed as OAwere collected. Patients who
had incomplete data were excluded. The diagnosis of RAwas
made according to the American College of Rheumatology/
European League Against Rheumatism Collaborative
Initiative 2010 criteria [15] and the diagnosis of OAwas based
on the 1986 clinical and radiological criteria for the diagnosis
of knee OA developed by the American College of
Rheumatology [16]. Finally, six patients with RAwere obtain-
ed and six patients with OA were selected by random. The
patients’ basic information and serologic profile are shown in
(Table 1). Informed consent was obtained from all subjects
and the study was approved by the local ethics committee
(Nanjing, China).
Immunoprecipitation
All SF samples were centrifuged at 25,000×g for 10 min at
4 °C and the supernatants were stored separately in sterile
conditions at −80 °C. EDTAwas added at a final concentration
of 50 mM, followed by centrifugation at 14,000×g for 10 min
at 4 °C, and the supernatant or sample was transferred to a new
vial. Protein concentrations were determined by BioSpec-
nano (Shimadzu Biotech, Kyoto, Japan), and 1 mg was then
subjected to immunoprecipitation [17,18]. Anti-citrulline
polyclonal antibody (pAb; Abcam, Cambridge, USA) was
cross-linked to protein G-Agarose (Sigma Aldrich, St Louis,
MO, USA) with stable amide linkages according to the man-
ufacturer’s instructions. Citrullinated proteins were
immunoprecipitated by incubating the supernatant/sample
with agarose-conjugated rabbit anti-citrulline antibodies over-
night. The samples were washed three times with 50 mM
ammonium acetate pH 7.4 and once with H2O, and the bound
peptides were then eluted with acetonitrile/H2O (7:3 v/v) con-
taining 5 mM HCl. The eluted peptides were subjected to
desalting by C18 tip (SciLifeLab, Shanghai, China). The effi-
ciency of immunoprecipitation was determined on equal
amounts of protein/sample (OA, RA, washes of RA, and elu-
ents of RA) by immunoblotting using anti-citrulline pAb.
Protein reduction, alkylation, and enzyme digestion
An additional 937 μL of 50 mM NH4HCO3 was added to the
eluted proteins. The proteins were reduced by adding 10μL of
0.5 M dithiothreitol (DTT) in 50 mM NH4HCO3 to a final
concentration of 4 mM and incubated for 20 min at 56 °C. For
alkylation, 27 μL of 0.55 M iodoacetamide was added, and
the samples were incubated for 15 min at room temperature in
the dark. The final concentration of the extracted proteins was
approximately 2.4 mg/mL (total volume approximately
1250 μL) according to the optical density at 280 nm.
ProteaseMax solution (10 μL of 1 %) was added together with
50μL of 1 μg/μL LysC before incubation in a hydrated cham-
ber at 37 °C overnight. The reaction was quenched by adding
formic acid (FA; Fluka, Sigma) to a final concentration of
0.5 %. The digested peptides were then subjected to desalting
by C18 tip (Shimadzu Biotech, Kyoto, Japan). Finally, the
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desalted peptides were immediately applied to a prominence
nano2D-HPLC and Accuspot™ system (Shimadzu Biotech,
Kyoto, Japan).
2D-NanoLC fractionation
A 5-μL aliquot of the desalted peptide/sample was loaded
directly onto a PolySulfoethyl A Column (1.0 mm×50 mm,
5 μm) for the first dimensional strong cation exchange sepa-
ration (A=10 mM FA, B=600 mM FA). The samples were
then subjected to a second dimensional RP separation using a
C a p i l l a r y EX -N a n o Mon oC a p C - 1 8 c o l um n
(0.16 mm×150 mm, 5 μm): A=5 % acetonitrile+0.1 % FA,
B=95 % acetonitrile +0.1 % FA. The flow rate of the system
was set at 4 μL/min post-split. The eluent passed through a
UV/Vis detector (220 nm) and was mixed with α-cyano 4-
hydroxycinnamic acid matrix (CHCA; 5 mg/ml in 50/50 ace-
tonitrile/0.1 % trifluoroacetic acid) and deposited onto a stain-
less steel MALDI target using the Accuspot™ LC-MALDI
deposition robot [19].
LC-MALDI-TOF/TOF MS analysis
Samples were deposited at a volume of ∼1 μL/spot. The
signal-to-noise ratio (S/N) was determined using Launchpad
version 2.9.1 software (Shimadzu Biotech, Kyoto, Japan).
The limit of detection (LOD) was established with a S/N of
3:1. The m/z value was calibrated with 50 fmol each of human
angiotensin II and human adrenocorticotropin fragment 18–39
and 250 fmol each of bovine insulin oxidized beta chain and
bovine insulin as external standards. The m/z reported in
MALDI-TOF/TOF (MALDI-7090, Shimadzu Kratos,
Manchester, UK) was set in positive ion mode and a mass
range of 1000–4000 Da. The peptide ions with high S/N
(S/N>10:1) were subjected to CID for subsequent MS/MS
analysis.
Bioinformatics analysis
The raw MS/MS data were searched using the Mascot engine
and then processed with PTM Finder™ Software (Shimadzu
Kratos) using the following criteria: database, Swiss-Prot,
Fig. 1 Schematic of the
citrullinated peptide detection
method. Step 1: citrullination of
the protein. Step 2: the hydrogen
bond is cleaved during CID of the
citrullinated peptides, resulting in
a signature 43-Da neutral loss
from peptidyl-citrulline
Table 1 Clinical and laboratory
















RA Female 61 >200 86.3 64 25.1 3 4.28
RA Female 79 >200 397 109 42.7 4 4.93
RA Female 73 >200 40.6 44 37.5 2 3.84
RA Male 69 >200 24.5 29 27.3 3 3.43
RA Male 63 >200 142 44 77.8 5 3.72
RA Male 70 >200 102 82 31.4 2 4.16
OA Female 68 <0.5 <20 8 8.9 2 _
OA Female 53 <0.5 <20 7 7.8 3 _
OA Female 63 <0.5 <20 5 2.5 2 _
OA Male 69 <0.5 <20 3 0.6 5 _
OA Male 54 <0.5 <20 7 4.3 4 _
OA Male 58 <0.5 <20 14 9.9 3 _
ACPA anticitrullinated protein antibody, RF rheumatoid factor, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, DAS28 disease activity score at 28 joints
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human; enzyme, LysC; miscleavages, 2; static modifications,
carbamidomethylation of cysteine (+57.02 Da); variable mod-
ifications, oxidation of methionine (+16.00 Da); neutral loss
of isocyanic acid from peptidyl-citrulline (−43.02 Da);
precursor ion tolerance, 0.3 Da; fragment ion tolerance,
0.8 Da. At this point, the citrullinated sites were iden-
tified by MS/MS analysis of the AA(8)AA ion because
an ornithine residue (Orn) was expected to be the prod-
uct after loss of a carbamyl group. Thus, the neutral
loss of isocyanic acid from peptidyl-citrulline could be
differentiated from the deamidation of peptidyl-
asparagine or peptidyl-glutamine. All entries were fil-
tered using a false positive rate of 1 % at the peptide
levels , and false posi t ives were removed. The
citrullinated proteins from the RA SFs were further an-
alyzed with DAVID Bioinformatics Resources (David
6.7 software, Bethesda, Maryland, USA) to understand
their biological functions.
Results
A total of 182 citrullinated peptides and 200 citrullinated sites
were identified in the RA SFs, while only three citrullinated
peptides and four citrullinated sites were identified in the OA
SFs (Tables 2 and 3). The 182 citrullinated peptides from the
RA SFs were derived from 83 autoantigens, and the three
citrullinated peptides from the OA SFs were derived from
three autoantigens. The autoantigens in the RA SFs were
over-citrullinated compared with the controls. Among these,
26 citrullinated proteins identified here have also been vali-
dated in previous studies (Table 4), which suggests that this
strategy for identifying citrullinated peptides is highly
effective.
Functional analysis of the identified citrullinated proteins
in the RA group was performed with David 6.7 software. The
categories of Bdisease^ and Bgene ontology^ reported a sig-
nificant enrichment of RA and acute inflammatory response-
associated genes, which corresponded to the physiological
status of the patients in the present study (Supplement
Fig. 1). Furthermore, genes involved in the enriched pathways
in the list were associated with complement and coagulation
cascades (Supplement Fig. 2). Additionally, proteins that were
involved in cell differentiation, metabolism, redox state and
apoptosis, regulation and transport, immune response and
acute phase, structural and cell adhesion, and other groups
based on the NCBI and UniProt database information are
shown in (Fig. 2a). Moreover, the proteins were also classified
by their subcellular location, as described in (Fig. 2b). The
results of our analysis demonstrated that the citrullinated pro-
teins obtained with our protocol provide reliable data on the
state of citrullination in RA SF.
Discussion
The major methods used currently to identify citrullinated
proteins employ 2D-PAGE followed by immunoblotting and
Fourier transform ion cyclotron resonance mass spectrometry
analysis. For example, J.B.C. van Beers et al. found 192 pro-
teins including 53 citrullinated proteins with their citrullinated
residues in RA SFs [12]. One problem with this method is the
small mass shift (+1 Da) from the conversion of peptidyl
arginine to Cit, which is challenging for mass detection to
distinguish. In the present study, citrullinated proteins were
effectively enriched following immunoprecipitation
(Supplement Fig. 1). NanoLC was then used to fractionate
the tryptic digests of citrullinated proteins to improve the sen-
sitivity and dynamic range of protein identification. With this
method, not only are peptides of the same nominal mass iso-
lated by temporal separation, but signal suppression is also
reduced because of the separation of low- and high-
abundance peptides. Importantly, the unique LC-MALDI
peak picking algorithm promotes the MS/MS of selected ions
at the apex of the eluting chromatographic peak to allow the
most efficient data acquisition. This is not often the case with
ES LC-MS/MS, where MS/MS acquisition is often taken on
the rising edge of the eluting chromatographic peak. In addi-
tion, the high-energy CID mode of MALDI-TOF/TOF
(20 keV collision energy, MALDI-7090) allowed us to deter-
mine the citrullinated sites more easily, according to the char-
acteristic neutral loss of an isocyanic acid group from
peptidyl-citrulline.
A number of chaperone molecules were identified within
the SFs, particularly heat shock 70 kDa protein 1A/1B
(HSPA1A), glucose-regulated protein 78 kDa (GRP78 or
HSPA5), and HSP90AA1, members of the stress-inducible
heat-shock protein 70 family. Also, we previously found
GRP75 (HSP70) and binding immunoglobulin protein (BiP
or GRP78) in RA synovial fibroblast-like synoviocytes
(FLSs) [20]. Citrullinated BiP induces anti-CCP and anti-
citrullinated fibrinogen antibodies and exacerbates collagen-
induced arthritis in mice, and deaminated HSP90 was
identified as a diagnostic autoantigen for a potentially serious
manifestation of RA [10,21]. Recently, HSPs have been re-
ported that not only act as chaperones during protein folding
but also play a role between ubiquitin E3 ligase and the pro-
teasome to inhibit proinflammatory NF-ΚB signaling [22]. In
addition, both canonical and non-canonical NF-ΚBs are
overexpressed in RA and are associated with the persistence
of inflammation in RA [23]. Thus, citrullination of HSP may
contribute to the chronic inflammation in the synovium or
dysregulation of RA synovial fibroblasts, suggesting that
citrullination may correlate with complement activation and
the perpetuation of RA.
In a previous study from our group, we also reported that
the elevated Annexin A11 in FLSs may be associated with the
2188 Clin Rheumatol (2016) 35:2185–2194
Table 2 Citrullinated peptides and their deaminized sites identified by MALDI-TOF-MS in the RA SFs
Gene name Protein ID Peptide sequence Citrullinated sites




ACTG1 ACTG_HUMAN DLYANTVLSGGTTMYPGIADRMQK R312
AGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQK R28






ANXA1 ANXA1_HUMAN DITSDTSGDFRNALLSLAK R177
GTDVNVFNTILTTRSYPQLRRVFQK R228















ARPC1B ARC1B_HUMAN QSSQRGLTARERFQNLDK R294, R299
PTLVILRINRAARCVRWAPNENK R100
C1R C1R_HUMAN GFLAYYQAVDLDECASRSK R149
MQTRAGSRESEQGVYTCTAQGIWK R420
DCGQPRNLPNGDFRYTTTMGVNTYK R388
C1S C1S_HUMAN AARLPVAPLRK R586
C2 CO2_HUMAN SSGQWQTPGATRSLSK R77










C4BPA C4BPA_HUMAN PELVNGRLSVDK R493
NLRWTPYQGCEALCCPEPK R353
C6 CO6_HUMAN FRCDSGRCIARK R150
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Table 2 (continued)
Gene name Protein ID Peptide sequence Citrullinated sites
RSENINHNSAFK R289
SSRTSNPYRVPANLENVGFEVQTAEDDLK R225
C9 CO9_HUMAN NFRTEHYEEQIEAFK R213
CAT CATA_HUMAN NAIHTFVQSGSHLAAREK R522
CD44 CD44_HUMAN NGRYSISRTEAADLCK R41
EQWFGNRWHEGYRQTPK R407, R413






CFHR2 FHR2_HUMAN SHSFRAMCQNGK R254
CFI CFAI_HUMAN DNERVFSLQWGEVK R480
THRYQIWTTVVDWIHPDLK R389
CHMP2A CHM2A_HUMAN MDLLFGRRK R8
DLVRTRRYVRK R71
CLC LEG10_HUMAN YQVMVNGQSSYTFDHRIK R115





CPB2 CBPB2_HUMAN DHEELSLVASEAVRAIEK R342
CTLA4 CTLA4_HUMAN AMHVAQPAVVLASSRGIASFVCEYASPGK R51
AQLNLATRTWPCTLLFFLLFIPVFCK R18
ENO1 ENOA_HUMAN TGAPCRSERLAK R403
LAQANGWGVMVSHRSGETEDTFIADLVVGLCTGQIK R372
F2 THRB_HUMAN YTACETARTPRDK R94, R97
DSTRIRITDNMFCAGYK R541




FGA FIBA_HUMAN NVRAQLVDMK R160
GLIDEVNQDFTNRINK R84
FGB FIBB_HUMAN REEAPSLRPAPPPISGGGYRARPAK R60, R72
EDGGGWWYNRCHAANPNGRYYWGGQYTWDMAK R445




GC VTDB_HUMAN HLSLLTTLSNRVCSQYAAYGEK R218
HQPQEFPTYVEPTNDEICEAFRK R149
RSDFASNCCSINSPPLYCDSEIDAELK R445
H1FX H1X_HUMAN VPWFDQQNGRTYLK R86
YSQLVVETIRRLGERNGSSLAK R57, R62
H2AFY H2AY_HUMAN SIAFPSIGSGRNGFPK R318
HABP2 HABP2_HUMAN EEFHEQSFRVEK R391
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Table 2 (continued)
Gene name Protein ID Peptide sequence Citrullinated sites
FCEIGSDDCYVGDGYSYRGK R203
LIANTLCNSRQLYDHMIDDSMICAGNLQK R480
HIST2H2AC H2A2C_HUMAN TRIIPRHLQLAIRNDEELNK R89
GNYAERVGAGAPVYMAAVLEYLTAEILELAGNAARDNK R43, R72
HMGB2 HMGB2_HUMAN MSSYAFFVQTCREEHK R24
HNRNPA1L2 RA1L2_HUMAN GGNFGGRSSGPYGGGGQYFAK R284
HP HPT_HUMAN VSVNERVMPICLPSK R261
YVMLPVADQDQCIRHYEGSTVPEK R311
HPR HPTR_HUMAN VLVNERVMPICLPSK R203
HPX HEMO_HUMAN NFPSPVDAAFRQGHNSVFLIK R102
HSP90AA1 Q8TBA7_HUMAN AQALRDNSTMGYMAAK R620
HNDDEQYAWESSAGGSFTVRTDTGEPMGRGTK R173
HSPA1A HSP71_HUMAN LLQDFFNGRDLNK R357
EIAEAYLGYPVTNAVITVPAYFNDSQRQATK R155
HSPA5 GRP78_HUMAN SDIDEIVLVGGSTRIPK R368
RLIGRTWNDPSVQQDIK R98
Ig kappa chain V-II region RPMI 6410 KV206_HUMAN VSNRDSGVPDRFSGSGSGTDFTLK R79
Ig lambda chain V-II region NEI LV202_HUMAN RPSGVSNRFSGSK R56, R63
Ig lambda chain V-II region NIG-84 LV211_HUMAN LLIYDVNSRPSGISNRFSGSK R56, R63
IGHA1 IGHA1_HUMAN YLTWASRQEPSQGTTTFAVTSILRVAAEDWK R282
IGHG3 IGHG3_HUMAN SCDTPPPCPRCPEPK R128
TPLGDTTHTCPRCPEPK R113
ING4 ING4_HUMAN WFCPRCSQERK R241
ITIH2 ITIH2_HUMAN RLSNENHGIAQRIYGNQDTSSQLK R475
TILDDLRAEDHFSVIDFNQNIRTWRNDLISATK R356, R359
KNG1 KNG1_HUMAN ICVGCPRDIPTNSPELEETLTHTITK R268
KRT33B KT33B_HUMAN ETMQFLNDRLASYLEK R66





LCP1 PLSL_HUMAN GDEEGVPAVVIDMSGLREK R316
ALENDPDCRHVIPMNPNTNDLFNAVGDGIVLCK R141
LGALS3BP LG3BP_HUMAN SGGSDRTIAYENK R514
SQLVYQSRRGPLVK R436
LRG1 A2GL_HUMAN ALGHLDLSGNRLRK R175
LQVLGKDLLLPQPDLRYLFLNGNK R239
MAPRE1 MARE1_HUMAN PLTSSSAAPQRPISTQRTAAAPK R168
MMP8 MMP8_HUMAN FYQLPSNQYQSTRK R52
MNDA MNDA_HUMAN INQEEVGLAAPAPTARNK R119
NCF1 NCF1_HUMAN SGQDVSQAQRQIK R292
STATDITGPIILQTYRAIANYEK R162
ORM1 A1AG1_HUMAN EQLGEFYEALDCLRIPK R167
PABPC1 PABP1_HUMAN AVTEMNGRIVATK R356
PVRIMWSQRDPSLRK R89, R94
ITGMLLEIDNSELLHMLESPESLRSK R604
PADI2 PADI2_HUMAN VGVFYVENPFFGQRYIHILGRRK R225, R233
PADI4 PADI4_HUMAN GFRLLLASPRSCYK R495
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extensive synovial fibroblast-like synoviocytes hyperplasia.
Additionally, in the extracellular environment defined as sy-
novial fluid, we found citrullinated AnnexinA1, another
member of the annexin superfamily of structurally related
Ca2+-dependent phospholipid-binding proteins. Several other
s tudies have demonstra ted that AnnexinA1 is a
Table 2 (continued)
Gene name Protein ID Peptide sequence Citrullinated sites
TLREHNSFVERCIDWNRELLK R536
PFGPVINGRCCLEEK R609
POFUT2 OFUT2_HUMAN VFVATDAVRK R337
DFIWGHRQDVPSLEGAVRK R315
PPIA PPIA_HUMAN EGMNIVEAMERFGSRNGK R148
PRG4 PRG4_HUMAN DQYYNIDVPSRTARAITTRSGQTLSK R1386, R1391
PRKCD KPCD_HUMAN QSMRSEDEAK R132
SPRDYSNFDQEFLNEK R628
IIGRCTGTAANSRDTIFQK R216
PTPN22 PTN22_HUMAN GPRNPPPTWNI R499
PAESVQSNNSSSFLNFGFANRFSK R491
SAA2 SAA2_HUMAN RGPGGAWAAEVISNARENIQRLTGRGAEDSLADQAANK R80, R89
SERPINA3 AACT_HUMAN ADLSGITGARNLAVSQVVHK R350
SERPINC1 ANT3_HUMAN LVSANRLFGDK R177
IPEATNRRVWELSK R78
ANSRFATTFYQHLADSK R89
SLC22A4 S22A4_HUMAN VPLTTSLFFVGVLLGSFVSGQLSDRFGRK R166
STAT4 STAT4_HUMAN NVSTLSNRRFVLCGTNVK R173
SLQSSSVSERQRNVEHKVAAIK R139
FHGNPMHVAVVISNCLREERRILAAANMPVQGPLEK R110
TAGLN2 TAGL2_HUMAN MANRGPAYGLSREVQQK R4
TF TRFE_HUMAN CSTSSLLEACTFRRP R696
EGYYGYTGAFRCLVEK R541
ADRDQYELLCLDNTRK R239, R251





TNC TENA_HUMAN VPEITRTVSGNTVEYALTDLEPATEYTLRIFAEK R1866
TNFAIP6 TSG6_HUMAN NFLAGRFSHL R273
VIM VIME_HUMAN MALDIEIATYRK R401
PDLTAALRDVRQQYESVAAK R270, R273
VPRPB VPRBP_HUMAN FISGTPRRK R707
SPFGSSFRTFNATDYK R1334
Citrullinated residues are indicated with a bold R
Table 3 Citrullinated peptides
and their deaminized sites
identified byMALDI-TOF-MS in
the OA SFs
Gene name Protein ID Peptide sequence Citrullinated sites
H3F3A H33_HUMAN DIQLARRIRGERA R130
PADI2 PADI2_HUMAN GFPVVLDSPRDGNLK R373
PADI4 PADI4_HUMAN TLPVVFDSPRNRGLK R372, R374
Citrullinated residues are indicated with a bold R
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glucocorticoid-induced molecule that can be transferred into
cartilage and can modulate T cell function and the adaptive
immune responses relevant to RA [24,25]. Consistent with
this, treatment of mice with dexamethasone promotes potent
antiarthritic effects that are dynamically attenuated in
AnxA1−/− mice [26]. Our observations on citrullinated
Annexin A1 reflect the possibility that citrullinated or non-
citrullinated Annexin may be a target to minimize glucocorti-
coid use in RA.
The different citrullinated sites of PADI2 and PADI4 in the
two groups suggest new potential biomarkers for RA. PADI2
and PADI4 are the only PAD isotypes expressed in the syno-
vial tissue of patients with RA, and they were reported to
induce differentiation and apoptosis [27]. PADI4, found in
the cell nucleus, mediated gene transcription by regulating
arginine citrullination and methylation in histones H1, H3,
and H4 and was autocitrullinated during cell activation
[8,28,29]. Interestingly, citrullinated H3F3A was found in
the OA controls, but not in the RA group. In addition, histones
H1x and H2Awere only citrullinated in the RA group. These
results suggest that PADI2 and PADI4 represent a heteroge-
neous subtype with different citrullinated sites targeting mul-
tiple structural domains, where the specific citrullinated site
may predict a specific disease. The exact mechanism under-
lying this phenomenon remains to be elucidated.
Although we identified the potential antigens for ACPA,
some limitations remain, including the amount of patients was
small, thus we pooled all samples per group to gain more
sensitivity and to find more citrullinated antigens; results
merely compared with previous studies; the validated process
used only one method of mass spectrometry and was only on
the basis of mass-spectrometry-based proteomics, so we per-
formed DAVID Bioinformatics Resources to classify these
genes corresponding to citrullinated proteins, at the same time,
estimate and verify the reliability. Further studies will employ
western blot to identify some selected potential autoantigens.
At the same time, we will collect samples of synovial fluid or
serum of RA patients as more as possible and then test anti-
bodies corresponding to autoantigens in synovial fluid or se-
rum of RA patients in order to obtain reliable results from
clinical data. These limitations indicate the need for larger
validation studies and prospective SFs studies in groups where
larger samples are available.
Overall, we demonstrated a simple and efficient strategy
for detecting citrullinated proteins and citrullinated sites in
human RA SFs. In addition to the previously detected
Table 4 26 citrullinated proteins in our study were validated in
previous studies
Protein ID References
Arginine deiminase type-4 [19]






C4b-binding protein alpha chain [12]
Complement C2 [12]
Complement C4-B [12]







Inter-alpha-trypsin inhibitor heavy chain H2 [12]






Vitamin D-binding protein [12]
Vimentin [11]
Fig. 2 Classification by a function and b subcellular location of the
proteins identified in the RA SFs
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citrullinated proteins in RA SF, the novel citrullinated proteins
identified by the data here may represent new antigens for
ACPAs, as well as new markers for diagnosis. More impor-
tantly, this data will contribute to the search for the
etiopathogenesis of, and new therapeutic targets for RA.
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